Search

Cannabidial – Stay Tuned

@LaughinPaulRyan | Wall Street Journal, Main Street and High Times

Stuart Titus – CEO of Medical Marijuana, Inc. $MJNA | The Stock Radio

We are pleased to announce a new Audio Interview with Stuart Titus, CEO of Medical Marijuana, Inc. Trading Symbol: MJNA – $MJNA Interviewee: Stuart

Source: Stuart Titus – CEO of Medical Marijuana, Inc. $MJNA | The Stock Radio

Kannalife And Medical Marijuana Inc. Join Forces

NEW YORK, Dec. 22, 2015 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (OTC Pink:MJNA) is proud to announce to shareholders and the public a joint effort with investment portfolio company Kannalife Sciences, Inc. (“Kannalife”) to open an opportunity for the public to “show their green” and participate in a fundraiser for research driven by Kannalife at Temple University for the potential use of cannabidiol as a treatment for chronic traumatic encephalopathy (CTE). CTE is the deadly concussion-related disease plaguing a high percentage of current and retired NFL football players and athletes participating in concussion-related sports.
As part of the fundraising initiative, Medical Marijuana, Inc. and Kannalife have co-sponsored and launched the “Show Your Green” public service announcement (PSA) to create awareness of CTE. Executives from both companies also explained to radio listeners on the U-T Community Spotlight radio show how to make a difference through medical research by visiting http://www.treatCTE.org.
At http://www.treatCTE.org, interested donors can “Show Your Green” by sharing photos along with the PSA video with their social networks. All funds committed will go directly into the CTE research being conducted by Kannalife at Temple University.
What is CTE?

Chronic traumatic encephalopathy is a life-threatening and debilitating disease and each football fan now has the opportunity to support awareness of CTE and make a move toward developing a treatment for the concussive injury. CTE is an oxidative stress (OS) related disease. Neural cells suffer functional or sensory loss in neurodegenerative diseases. Apart from several other environmental or genetic factors, oxidative stress leading to free radical attack on neural cells contributes a calamitous role in neurodegeneration.

Leading the “Show Your Green” PSA at http://www.treatCTE.org is Kannalife’s advisory board member and former NFL star defensive lineman, Marvin Washington. Washington now leads Kannalife’s efforts to expand on raising awareness for the disease and the need for a community-driven effort to support the research and development of therapeutic treatments to fight CTE. Speaking out on CTE and the NFL concussion lawsuit, Washington is calling on the public to “follow the signs” and “follow the science” in interviews including: ESPN’s Outside the Lines, NowThis, MSNBC, and Fox News Sports Court.

From 1988 to 1999, Washington played in 155 games over 11 seasons in the NFL, recording over 40 sacks in his eight years with the New York Jets, two years with the San Francisco 49’ers and as a member of the 1998 Superbowl champion Denver Broncos. Having been diagnosed with three known concussions and a countless number of subconcussions, the former NFL star is extremely passionate about helping individuals who are battling the debilitating and often deadly effects of CTE.

At http://www.treatCTE.org, Washington narrates the first of a short series of “Show Your Green” public awareness campaign videos, as he shares facts about CTE including:
When a football player takes a hit, the impact to the brain is 98 times the force of gravity

A recent study shows that 96% of former NFL players tested positive for CTE

CTE has been linked to dementia, depression and suicide; and

There is currently no effective treatment for CTE
Who is researching CTE?

Kannalife Sciences, Inc. (“Kannalife”), an MJNA portfolio company, is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife currently holds two licenses with the National Institutes of Health for U.S. Patent 6,630,507 “Cannabinoids as Antioxidants and Neuroprotectants.” These licenses are currently in use by Kannalife to develop novel therapeutic drugs to treat chronic traumatic encephalopathy (CTE) and hepatic encephalopathy (HE): http://www.google.com/patents/US6630507. Kannalife’s scientific team has researched the effects of cannabidiol (CBD) on non-differentiated native neuronal cells and has determined cannabidiol’s potential as a target drug candidate to treat oxidative stress-related disorders, CBD’s therapeutic index, and CBD’s limitations in pharmaceutical target drug design.
In tandem with its findings on CBD, Kannalife has developed a new cannabidiol-like molecule called KLS-13019 that, through pre-clinical testing and pharmacokinetic (PK) studies, indicates improvement over CBD’s role as a neuroprotectant through increased potency, as well as potential for greater safety through reduced toxicity. Side-by-side comparisons between CBD and KLS-13019 have also shown that KLS-13019 has marked improvements over CBD in oral bioavailability, CNS penetration, blood-plasma concentrations, and cognitive improvement in murine behavioral models.
How can you help?

You can “Show Your Green” and assist in raising awareness in the fight for a cure for CTE though medical research, by going to http://www.treatCTE.org for details.

Medical Marijuana Inc. – Kannalife PSA

NEW YORK, Dec. 10, 2015 (GLOBE NEWSWIRE) — To address the public’s questions about CTE, what the disease is and who it impacts — Medical Marijuana, Inc. (OTC Pink:MJNA) and its portfolio company Kannalife Sciences, Inc. (“Kannalife”) and phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators — are responding with a social media-driven campaign titled “Show Your Green.”

Leading the “Show Your Green” PSA is Kannalife’s advisory board member and former NFL star defensive lineman, Marvin Washington. From 1988 to 1999, Mr. Washington played in 155 games over 11 seasons in the NFL, recording over 40 sacks in his eight years with the New York Jets, two years with the San Francisco 49’ers and as a member of the 1998 Superbowl champion Denver Broncos. Mr. Washington now leads Kannalife’s efforts to expand on raising awareness for the disease and the need for a community driven effort to support the research and development of therapeutic treatments to fight CTE. Having been diagnosed with three known concussions and a countless number of subconcussions, the former NFL star is extremely passionate about helping individuals who are battling the debilitating and often deadly effects of CTE.
In “Show Your Green,” Mr. Washington narrates the first of a short series of “Show Your Green” public awareness campaign videos, as he shares facts about CTE including:
A recent study shows that 96% of former NFL players tested positive for CTE

CTE has been linked to dementia, depression and suicide; and

There is currently no effective treatment for CTE

The “Show Your Green” awareness campaign call-to-action is to post a photo featuring green “eye black” and then sharing the photo within the respondent’s social sphere of influence. By watching “Show Your Green,” every football fan from toddler to titan can have the opportunity to join in and show their green in support of increasing awareness of CTE and the drive towards developing a treatment for concussive injury and CTE, a life threating and debilitating disease. CTE is an oxidative stress (OS) related disease. Neural cells suffer functional or sensory loss in neurodegenerative diseases. Apart from several other environmental or genetic factors, oxidative stress leading to free radical attack on neural cells contributes a calamitous role in neurodegeneration.
Kannalife currently holds two licenses with National Institutes of Health for U.S. Patent 6,630,507 “Cannabinoids as Antioxidants and Neuroprotectants.” These licenses are currently in use by Kannalife to develop novel therapeutic drugs to treat chronic traumatic encephalopathy (CTE) and hepatic encephalopathy (HE): http://www.google.com/patents/US6630507. Kannalife’s scientific team has researched the effects of cannabidiol (CBD) on non-differentiated native neuronal cells and has determined cannabidiol’s potential as a target drug candidate to treat oxidative stress-related disorders, CBD’s therapeutic index, and CBD’s limitations in pharmaceutical target drug design.
“It is a positive step forward to see increased social awareness of traumatic head injury and CTE as well as a call-to-action by the public to creatively drive medical research for a solution,” states Dr. Stuart Titus, Chief Executive Officer of Medical Marijuana, Inc. “A head injury can affect people of all ages – not just NFL players.” Dr. Titus continues, “Kannalife’s efforts are focused on developing a neuroprotective pharmaceutical compound that may have far-reaching implications for furthering the science of neurological medicine. The Company aims to improve quality of life for patients and sufferers of concussions and CTE. The end goal is to end the suffering of patients and their families, who in later stages have been torn apart by the long-term degenerative effects of this terrible condition.”
In tandem with its findings on CBD, Kannalife has developed a new cannabidiol-like molecule called KLS-13019 that, through pre-clinical testing and pharmacokinetic (PK) studies, indicates improvement over CBD’s role as a neuroprotectant through increased potency, as well as potential for greater safety through reduced toxicity. Side-by-side comparisons between CBD and KLS-13019 have also shown that KLS-13019 has marked improvements over CBD in oral bioavailability, CNS penetration, blood-plasma concentrations, and cognitive improvement in murine behavioral models.
You can “Show Your Green” and assist in raising awareness in the fight for a cure for CTE though medical research, by going to http://www.treatCTE.org for details. Campaign spokespersons will be featured Friday, Dec. 11 at 9:00 am – 9:27 am PT on the U-T Community Spotlight Radio Show; the live broadcast can be heard online at http://www.wsradio.com. An archive of the interview can be accessed at http://www.wsradio.com/ut-san-diego/.

New Real Scientific Hemp Oil™ Liquid Product Line Now Available for Import Into Brazilian Market

SAN DIEGO, Nov. 23, 2015 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to announce the immediate release of its new line of Real Scientific Hemp Oil™ (RSHO™) products with medium-chain triglyceride (MCT) oil for import into Brazil, through its exclusive distributor HempMeds Brasil™. This new liquid product line is an all-natural, non-GMO hemp oil formulation with MCT oil.

“Convenience is key,” states Stuart W. Titus, PhD and Chief Executive Officer of Medical Marijuana, Inc. “After listening to our customers who are using RSHO™ hemp CBD oil, we discovered that many were blending RSHO™ with coconut and/or MCT oil to optimize the consistency when providing it to their children. With the new RSHO™ liquid formulation of MCT oil and convenient dosing spoon, we are simplifying administering the product. We are extremely excited and pleased with this new product line and feel that the popularity of RSHO™ will further expand, as a result of making it more convenient for consumers to use.”

The new RSHO™ liquid is now measured in milliliters. This will allow doctors to prescribe the liquid in a measured dosage they are more familiar with.

RSHO-Liquids-6

MCT oil is found naturally in popular food items, including coconut oil and is a top source of essential healthy fats that are popular with athletes, culinary experts and health and nutrition professionals worldwide, as explained by WebMD.

HempMeds Brasil™ is now making available three new, all-natural hemp oil products with MCT oil:

  1. Real Scientific Hemp Oil™ [RSHO™] new cannabidiol (CBD) liquid products with MCT oil in Gold.
  2. Real Scientific Hemp Oil™ [RSHO™] new cannabidiol (CBD) liquid products with MCT oil in Blue.
  3. Real Scientific Hemp Oil™ new cannabidiol (CBD) in convenient capsules.

Currently on a case-by-case basis, residents of Brazil who have a government-recognized medical indication and want access to RSHO™ hemp oil products, may do so with a doctor’s prescription and formal import approval from ANVISA. The government agency also explains on its website how to apply for an import certificate. HempMeds Brasil™ has been preparing for more than a year, its formal product application and regulatory submission, a process which is expected to be completed by 2016.

map_us270

In the U.S. hemp is widely regarded as a whole food and super-food. Medical Marijuana, Inc.’s cannabidiol (CBD) hemp oil is derived from the mature stalk of the hemp plant and is considered a food nutrient delivering the benefits of cannabinoids without the psychotropic/euphoric effects of THC. Non-GMO RSHO™ contains no pesticides, herbicides or heavy metals. Before becoming a finished product, RSHO™ goes through multiple quality tests by top cannabis industry and food laboratories.

For additional information on the new RSHO™ MCT oil products available for import, visit the HempMeds Brasil™ website here.

Source: GlobeNewsWire

The Significance of the ‘507 Patent

FACT: The National Institutes of Health has a patent on the therapeutic uses of CBD. 

In 1998, a group of scientists on behalf of the National Institutes of Health filed a patent with the US Patent Office that stated that cannabinoids have medical value.

Co-authored by Nobel Laureate Julius Axelrod, Patent #6,630,507 was awarded to the National Institutes of Health in 2003, just five years after it was filed. This patent is titled, “Cannabinoids as antioxidants and neuroprotectants.”

FACT: The NIH acknowledges the therapeutic properties and potential uses of CBD. 

Colloquially called “the ‘507 patent,” this document describes the potential therapeutic values of non-psychoactive cannabinoids. It describes cannabidiol (CBD) in particular as being a potent antioxidant – stronger than either vitamin C and vitamin E. CBD is also described as having neuroprotective properties, meaning the NIH believes it may protect the brain and nervous system from damage due to head trauma like concussions or brain damage from strokes.

The patent also describes CBD as being very non-toxic, with no possibility of fatal overdose and no damage demonstrated “large, acute doses” of 700mg CBD/day (which is hundreds of times more CBD than most people would ever ingest).

FACT: This patent flies in the face of the Schedule I status of cannabis, which defines cannabis as having “no medical value.”

The US government doesn’t officially recognize the medical potential of marijuana, at least in part because the studies about its potential therapeutic benefits have been small, and there have been no large-scale clinical trials on the plant. However, certain components of marijuana have been made into pharmaceutical drugs for decades like Marinol, which is a synthetic version of THC to treat chemotherapy symptoms.

FACT: The ‘507 patent also means anyone wanting to develop a pharmaceutical drug using CBD would have to receive a license from the NIH to do so.

Fortunately, we have that covered. Medical Marijuana Inc.’s joint venture with KannaLife Sciences includes exclusive and non-exclusive license agreements with the NIH to develop CBD into viable medicines. This is yet another way that we are working towards a future in which cannabinoids are viewed as the true therapeutic powerhouses emerging research indicates they are.

FACT: Contrary to popular belief, this patent isn’t for medical marijuana.

The ‘507 patent covers the potential medical use of non-psychotropic compounds in cannabis, particularly CBD. The ‘507 patent specifically avoids psychotropic cannabinoids (like THC). 

FACT: The ‘507 Patent is among the strongest cases for our CBD business model.

Legitimacy is everything in this world. Operating with the knowledge that one of the most venerable institutions in the world has cataloged the many potential benefits of CBD motivates every business decision we make.

Source: Medical Marijuana Inc.

Rep. Blumenauer, Other Members Urge President Obama to Find New Leadership for DEA

Washington, DC (November 19, 2015) – Today, Representative Earl Blumenauer (D-OR), joined by Representatives Dana Rohrabacher (R-CA), Steve Cohen (D-TN), Sam Farr (D-CA), Barbara Lee (D-CA), Ted Lieu (D-CA), and Jim McDermott (D-WA), sent a letter to President Obama calling for new leadership at the Drug Enforcement Administration (DEA) following recent comments by the Acting Administrator, referring to the notion of smoking medical marijuana as ‘a joke.’

“Mr. Rosenberg’s comments are outrageous and misleading. The last 20 years has shown overwhelming testimonial evidence of the benefits of medical marijuana, leading 23 states, DC, and Guam to change their laws,” said Representative Blumenauer. “President Obama has taken action to respect state medical marijuana laws. Mr. Rosenberg is out of step with the Administration and out of touch. It’s time for new leadership.”

In the letter, the lawmakers also call out Rosenberg’s hypocrisy in statements he made highlighting a lack of information demonstrating the safety or effectiveness of marijuana as medicine. Current federal policies make it very difficult for doctors and scientists to conduct the medical research with marijuana necessary to obtain this information, and the DEA has been integral to limiting access to marijuana that can be legally used for research.

“The real joke is that the DEA has played a huge role in propping up federal policies that have systematically blocked research of marijuana’s medicinal value. If there are any questions about its safety or effectiveness, it’s because the federal government continues to stymie science,” said Representative Blumenauer.

Yesterday, November 18, Representative Blumenauer took to the floor of the House calling for a new DEA chief. Additionally, a petition organized by Marijuana Majority on Change.org demanding that Rosenberg be fired has garnered more than 90,000 signatures.

ANVISA – Brazil’s Government Health Agency – Approves Patient’s Request for Medical Marijuana, Inc.’s Real Scientific Hemp Oil™ for a New Indication: Parkinson’s Disease

SAN DIEGO, Nov. 18, 2015 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to announce to shareholders and to the public that its flagship product Real Scientific Hemp Oil™ (RSHO™) has again made world history as a cannabis product to be approved on a case-by-case basis for Parkinson’s disease by the Brazilian Government Health Agency ANVISA – which is responsible for approving citizen importation of medicines and botanical remedies from outside of Brazil.

Real Scientific Hemp Oil(TM) – RSHO(TM) – Approved for Import by Brazil Government’s ANVISA with Import Authorization.

Following Epilepsy (CDKL5 and Dravet Syndrome), which was tSpt indication to be approved, Parkinson’s disease becomes the second approved indication of Medical Marijuana, Inc.’s RSHO™ by Brazil’s ANVISA for importation with medical recommendation. Medical Marijuana, Inc. and its partner company HempMeds Brasil™ are working diligently within the framework of the Brazilian Government for approvals of at least five other indications.

wpid-rshobama.png

MJNA’s partner HempMeds Brasil™ is providing the RSHO™ exclusively for the Brazilian marketplace while under temporary case-by-case approval for several additional medical indications, subject to clinical trials within the country.

Today, any resident of Brazil who has a government-approved medical indication and who would like to have access to RSHO™ hemp oil products, may do so with a doctor’s prognosis, prescription and government-approved import documentation. ANVISA has issued a statement on the agency’s website and has also made an effort to explain how to apply for an import certificate. HempMeds Brasil™ has been working for over a year on its formal product application and regulatory submission. The company expects this to take at least through 2015 to complete.

“The government of Brazil with their 1988 Constitutional right of free health care (SUS) to all citizens is again leading the way by putting the well-being of their people first,” states Stuart W. Titus, PhD – CEO of Medical Marijuana, Inc. “RSHO™ products have been provisionally approved and are being reviewed for potentially five other medical indications, which are subject to future clinical trials – and the Company will continue to update shareholders on further developments.”

In 2005, the number of Parkinson’s patients worldwide was between 4.1 and 4.6 million. By the year 2030, those numbers are expected to more than double to 8.7 and 9.3 million patients according to this report published by the European Parkinson’s Disease Association. The Parkinson’s Disease Foundation states, in the U.S. alone, Parkinson’s is estimated to cost nearly $25 billion every year in combined direct and indirect costs.

Hemp is widely regarded as a “whole food” and “super food.” MJNA’s cannabidiol(CBD) hemp oil is derived from the mature stalk of the hemp plant and is considered a food nutrient delivering the benefits of cannabinoids without the psychotropic/euphoric effects of THC. Although CBD hemp oil products from MJNA are readily available in and ship to all U.S. states, territories, and districts, hemp oil products are handled quite differently in Brazil.

Until recently, the Brazilian government treated anything derived from cannabis – even hemp – as illegal and, therefore, a controlled substance. In a series of landmark rulings, the Brazilian government began permitting the importation of hemp CBD oil products – including RSHO – with registration by the Federal government agency ANVISA. The Federal government agency also removed CBD from its prohibited substance use list.

For information on the indication of Parkinson’s disease in Brazil and to learn how to import cannabidiol for Parkinson’s disease, visit the HempMeds Brasil™ website here.

Create a free website or blog at WordPress.com. | The Baskerville Theme.

Up ↑

Follow

Get every new post delivered to your Inbox.

Join 1,262 other followers